30th May 2026
Rubicon Research Limited Q4 FY2026 Audited Financial Results. Rubicon Research Limited, a provider of contract formulation development services to pharmaceutical companies, announced its Q4 FY2026 and FY2026 results. The Company reported a strong financial performance for the quarter and year ended March 31, 2026, with net profit for the quarter rising 112 percent. Revenue growth for the company was broad-based, with the top 5 products contributing 39% of revenue in Q4 FY2026,
